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SUMMARY
Pancreatic cancer is an aggressive malignancy with morbidity rates almost equal to mortality rates
because of the current lack of effective treatment options. Here, we describe a targeted approach
to treating pancreatic cancer with effective therapeutic efficacy and safety in noninvasive imaging
models. We developed a versatile expression vector ‘‘VISA’’ (VP16-GAL4-WPRE integrated systemic
amplifier) and a CCKAR (cholecystokinin type A receptor) gene-based, pancreatic-cancer-specific
promoter VISA (CCKAR-VISA) composite to target transgene expression in pancreatic tumors
in vivo. Targeted expression of BikDD, a potent proapoptotic gene driven by CCKAR-VISA, exhibited
significant antitumor effects on pancreatic cancer and prolonged survival in multiple xenograft and
syngeneic orthotopic mouse models of pancreatic tumors with virtually no toxicity.INTRODUCTION
Pancreatic cancer is one of the most aggressive human
malignancies, and approximately 37,170 new cases will
be diagnosed in 2007 in the United States (Jemal et al.,
2007). Despite efforts over the past three decades to im-
prove diagnosis and treatment, the prognosis of patients
with pancreatic cancer is extremely poor with or without
treatment, and no effective markers have been found for
early diagnosis or effective therapy. Nearly 50% of pa-
tients have metastatic diseases at diagnosis, and nearly
100% of patients develop metastases and die of the dis-
ease. The survival rates for patients with pancreatic can-
cer are the lowest of all cancers; the overall 5 year survival52 Cancer Cell 12, 52–65, July 2007 ª2007 Elsevier Inc.rate is less than 4%. At any stage, pancreatic cancer re-
sponds poorly to chemotherapy and radiation therapy.
Management in most cases is palliative because chemo-
therapy and radiotherapy are not curative (Bardeesy and
DePinho, 2002; Hingorani et al., 2005; Jaffee et al., 2002;
Li et al., 2004). Therefore, an effective strategy for the
treatment of pancreatic cancer is urgently needed.
At least two substantial obstacles exist in developing
a safe and effective gene therapy strategy for treating pan-
creatic cancer, however—the lack of a pancreatic-cancer-
specific expression vector with strong activity and stringent
specificity and the lack of a convenient animal model for
spatiotemporal monitoring of tumor growth and metas-
tasis. Recently reported pancreatic-cancer-specific orSIGNIFICANCE
Gene therapy for pancreatic cancer has been tested, but its development has been hampered by concerns with
safety and efficacy and the limitations of conventional animal models. This report describes a robust pancre-
atic-cancer-specific expression vector, CCKAR-VISA, and its application in pancreatic tumor-bearing mouse
models. Systemic administration of CCKAR-VISA-driven BikDD, a potent proapoptotic gene, in DNA:liposome
complexes vigorously repressed growth of pancreatic tumors and metastasis and prolonged survival in multiple
orthotopic mouse models. These findings constitute a strategy for potentially eliminating pancreatic cancer safely
and effectively and highlight useful models for noninvasive spatiotemporal monitoring. The newly developed VISA
system is also a versatile tool to boost other tissue- or cancer-specific promoters for developing promising ther-
apeutics for other diseases.
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2005; Li et al., 2006; Su et al., 2005; Wang et al., 2004;
Wesseling et al., 2001) show much lower activity than the
commonly used strong cytomegalovirus (CMV) enhancer/
promoter, which is ubiquitously active. The efficacy of
gene therapy depends greatly on the efficiency of trans-
gene expression after systemic delivery. Therefore, one of
our goals in the current study was to develop a pancre-
atic-cancer-specific expression vector that would not
only maintain pancreatic cancer specificity but also
produce robust activity, i.e., activity stronger than or com-
parable to that of the CMV promoter-driven expression
vector, in pancreatic cancer cells but much lower activity
in normal cells.
Bioluminescent imaging has been used to monitor the
growth of solid tumors and lymphomas in the abdomen
and to detect in vivo cell proliferation, signal transduction
pathways, and apoptosis in animal models (El-Deiry et al.,
2006; Gelovani Tjuvajev and Blasberg, 2003; Gross and
Piwnica-Worms, 2005; Thorne et al., 2006; Xie et al.,
2004). Recently, we generated an EZC-prostate model in
which the prostate glows because of the expression of
firefly luciferase in prostate epithelial cells (Seethamma-
gari et al., 2006; Xie et al., 2004) and imaged targeted fire-
fly luciferase activity in the endothelial cells of xenografts
in vivo by using an IVIS imaging system (Xenogen, Ala-
meda, CA) (Ou-Yang et al., 2006). The advantages of this
imaging technique for pancreatic cancer gene therapy are
its ability to monitor and allow optimization of gene ther-
apy protocols and to detect the growth and metastases
of pancreatic tumors in real time without having to kill
the animals. In this study, we used pancreatic cancer
cell lines (AsPC-1-Luc and Panc02-Luc) made to stably
express firefly luciferase enzyme and established ortho-
topic pancreatic cancer xenograft models in which the
growth and metastasis of the tumors can be noninvasively
monitored by a live-animal imaging system.
All roads to successful eradication of cancer cells by
nonsurgical modalities exploit the induction of apoptosis
(Hanahan and Weinberg, 2000; Reed, 2003). The BH3-
only group of the Bcl-2 family, central regulators of the
mitochondrial pathway of apoptosis, serves as sentinels
for cellular derangement (Boyd et al., 1995; Han et al.,
1996). Of the BH3-only members (Bad, Bik, Noxa, HRK,
Puma, BMF, Bid, and Bim), Bik (Bcl-2 interacting killer)
in particular demonstrates not only the greatest binding
affinity for Bcl-2 and Mcl-1 but also the broadest binding
pattern (Bcl-2, Bcl-XL, BCL-w, and Mcl-1) compared
with the other BH3 members (Certo et al., 2006). We pre-
viously demonstrated that systemic delivery of the Bik
gene by liposomes significantly inhibited the growth and
metastasis of human breast cancer in nude mice (Zou
et al., 2002). Bik expression by adenovirus has also been
reported to trigger apoptosis of human malignant glioma
cells in vivo (Naumann et al., 2003). More recently, we de-
veloped a Bik mutant (BikDD) in which changes were
made in T33D and S35D to mimic phosphorylation at
these two residues, enhancing their binding affinity with
the antiapoptotic proteins Bcl-XL and Bcl-2. This mutantwas more potent than Bik wild-type and other Bcl-2 family
proapoptotic genes, such as Bad, Bak, and Bok, in induc-
ing apoptosis and inhibiting cell proliferation in various
human cancer cells (Chen et al., 2004; Day et al., 2006;
Li et al., 2003).
Thus, our purpose in undertaking this study was three-
fold: to develop an active, pancreatic-specific expression
vector for delivering the apoptotic gene BikDD specifically
to pancreatic cancer cells; to test the effectiveness of this
expression vector in the orthotopic mouse models of pan-
creatic cancer; and to demonstrate the feasibility of imag-
ing the gene delivery and its aftermath in real time in living
animals.
RESULTS
The Molecularly Engineered CCKAR-Based
Expression Vector, C-VISA, Is Robust, Specific
to Pancreatic Cancer Cells, and Prolongs
Transgene Expression
CCKAR has been shown to be overexpressed in human
pancreatic ductal adenocarcinomas (PDAC) or human
PDAC cell lines compared to normal human pancreatic
ductal epithelium (HPDE) (Goetze et al., 2000; Jang et al.,
2005; Moonka et al., 1999; Weinberg et al., 1997). We also
examined the CCKAR expression in nine human PDAC
specimens from patients and found that the endogenous
CCKAR mRNA was overexpressed in 77.7% (7 of 9) of
the human PDAC tumors but undetectable in the human
normal pancreatic tissue (see Figure S1A in the Supple-
mental Data available with this article online), consistent
with reports from several independent groups as indicated
above. We have also previously shown that the CCKAR
promoter is selectively active in pancreatic cancer cells
as compared with other normal cell lines (Li et al., 2006).
Although the CCKAR promoter is active in and specific
to pancreatic cancer cells, its activity is less than 0.3%
of that of the CMV promoter (Figure 1B). Such low activity
would lead to very poor efficacy in gene therapy settings
(Conwell and Huang, 2005; Qiao et al., 2002; Reynolds
et al., 2001; Xie et al., 2001). To enhance the efficiency
of its pancreatic-cancer-specific expression, we first engi-
neered one copy of the 0.8-kb WPRE (the posttranscrip-
tional regulatory element of the woodchuck hepatitis virus)
(Glover et al., 2002; Zufferey et al., 1999) downstream of
the luciferase gene to posttranscriptionally regulate lucif-
erase gene expression, producing the plasmid CCKAR-
Luc-WPRE (C-P-Luc) (Figure 1A). The activity of C-P-Luc
in the PDAC cell lines AsPC-1, PANC-1, and Panc02 was
increased by 3.9-, 2.6-, and 3.1-fold, respectively, com-
pared with the CCKAR promoter (Figure 1B). However, as
compared with the CMV promoter, the C-P-Luc promoter
was still too weak. Because the two-step transcriptional
amplification (TSTA) system can significantly amplify the
activity of the prostate-specific antigen (PSA) promoter
(Iyer et al., 2001; Zhang et al., 2003), we reasoned that the
activity of the CCKAR promoter could be augmented by
using the TSTA system. To test this hypothesis, we gener-
ated the plasmid CCKAR-TSTA-Luc (C-T-Luc) (Figure 1A).Cancer Cell 12, 52–65, July 2007 ª2007 Elsevier Inc. 53
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Targeting Eradication of Pancreatic CancerFigure 1. Molecularly Engineered CCKAR-Based Promoter C-VISA Is Robust, Prolongs Duration of Gene Expression, and Is Pan-
creatic Cancer Specific
(A) Schematic diagram of engineered CCKAR-based constructs.
(B) Activity of CCKAR-based promoters in pancreatic cancer cells and pancreatic acinar cells. The data represent the mean of four independent
experiments. Error bars indicate SD.
(C) Kinetics of luciferase activity driven by CMV, C-TSTA, or C-VISA promoter. AsPC-1 and Panc02 cells were transiently transfected with the indi-
cated plasmid DNA and were imaged with the IVIS imaging system. The photon signals (photons/sec) of luciferase expression were plotted. The data
represent the mean of two independent experiments. TEI, total expression index.
(D) Tissue specificity of the C-VISA promoter. Shown is the percentage of the dual luciferase ratio for each cell line relative to the dual luciferase ratio
for AsPC-1 cells which is set at 100%. The data represent the mean of four independent experiments. Error bars indicate SD.Indeed, the TSTA system dramatically amplified the
CCKAR promoter activity in AsPC-1, PANC-1, and Panc02
cells (826-, 256-, and 353-fold increases, respectively, in
comparison with the activities of the CCKAR promoter)
(Figure 1B). To generate a more active expression vector
based on these findings, we then combined the WPRE
element into the TSTA system to produce a VISA (VP16-
Gal4-WPRE integrated systemic amplifier) system. The
CCKAR promoter was fused to the VISA system to pro-
duce CCKAR-VISA (C-VISA) (Figure 1A). Luciferase activ-
ity with the C-VISA promoter was increased by 1140-,
297-, and 600-fold in AsPC-1, PANC-1, and Panc02 cells,
respectively, relative to the CCKAR promoter alone (Fig-
ure 1B). Overall, the C-VISA activity reached 287.8%,
67.6%, and 138.5% of the activity of the CMV promoter
in AsPC-1, PANC-1, and Panc02 cells, respectively, at 2
days after transfection (Figure 1B). To ensure the general-54 Cancer Cell 12, 52–65, July 2007 ª2007 Elsevier Inc.ity of C-VISA for high-level expression in human PDAC, we
further examined the activities of these constructs in 11
more human PDAC cell lines available. As shown in Fig-
ure 1B and Figure S1B, C-VISA exhibited a general strong
activity in all 13 human PDAC cell lines tested, with a 557-,
152- and 1.5-fold increase as compared with CCKAR(C),
CCKAR-WPRE (C-P), and CCKAR-TSTA (C-T), respec-
tively. On average, the C-VISA activity was as high as
85.5 ± 21.7% of the CMV activity in all 13 human PDAC
cell lines (Figure 1B and Figure S1B). Importantly, the
C-VISA vector was also robust in the primary cultured
pancreatic cancer cells (PL5), with 42.5% of the CMV pro-
moter and resulting in a 607-, 250-, and 1.50-fold increase
as compared with C, C-P, and C-T, respectively (Fig-
ure 1B). To ensure that C-VISA is not active in pancreatic
acinar cells, we further measured the activity of C-VISA in
the pancreatic acinar cell line AR442J (Sata et al., 1999).
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Targeting Eradication of Pancreatic CancerFigure 2. C-VISA Transcriptionally Targets Transgene Expression to Pancreatic Cancer in Animal Models
(A) Luciferase expression driven by the C-VISA promoter is more robust and more persistent in AsPC-1 tumors. Subcutaneous AsPC-1 tumors in nude
mice were intratumorally injected with 50 mg of liposomal plasmid DNA. Shown are representative images (upper panel) from each group of four mice
and the quantified photon signals (photons/s) (lower panel). Error bars indicate SEM.
(B) Luciferase expression driven by C-VISA promoter is undetectable in Hep3B tumors. Hep3B tumors in nude mice were intratumorally injected as
described in (A). Mice underwent imaging 2 days after injection. Shown are representative images (left panel) from each group of four mice and the
quantified photon signals (photons/s) (right panel). Error bars indicate SEM.
(C–F) The C-VISA promoter targets the luciferase expression to pancreatic cancer in an orthotopic model of AsPC-1 tumors after systemic admin-
istration. Nude mice bearing orthotopic AsPC-1 tumors were intravenously injected with 50 mg of liposomal DNA. Mice were subjected to in vivo
imaging (C). The lungs/hearts and pancreata with tumors from mice from (C) were subjected to ex vivo imaging (D). The photon signals were quantified
(shown on the right). Tissue specimens from tumors and specified organs dissected from mice in (C) at 2 days after systemic delivery were measured
for luciferase activity with a luminometer (E). The data are expressed as relative light units (RLU) per milligram of total protein. Tissue specimens from
(E) were fixed and processed for immunohistochemical analysis of firefly luciferase expression [(F) and data not shown]. Error bars indicate SD; Pan,
pancreas; Spl, spleen; Kid, kidney; Inte, intestine; Mus, muscle.The data showed that the C-VISA activity was as low
as 0.4% of the CMV promoter activity in AR42J cells
(Figure 2B), suggesting that it may remain very low in the
pancreatic acini, thus, in favor of its application to gene
therapy for pancreatic cancer. Because WPRE increases
the half-life of the RNA transcripts (Zufferey et al., 1999),
we reasoned that WPRE in the C-VISA vector might pro-
long the duration of transgene expression. To test this,
we measured the kinetics of the luciferase activity in
AsPC-1 and Panc02 cells after transient transfection. In-
deed, C-VISA significantly prolonged the duration of lucif-
erase gene expression in both cell lines (Figure 1C). Forinstance, on the fifth day after transfection, the activity of
luciferase induced by the CMV promoter had almost com-
pletely disappeared, whereas the activity induced by C-
VISA was still robust in both cell lines. The total expression
index (TEI) of C-VISA (in comparison with the area under
the curve of luciferase activity in Figure 1C, with CMV ac-
tivity set as 1) was 3.1 in AsPC-1 cells and 3.8 in Panc02
cells. The significantly improved TEI of the therapeutic
gene should further improve the efficacy of gene therapy.
Most importantly, C-VISA remained low in nonpancreatic
cancer cells (liver, prostate, ovary, breast, uterine cervix,
and brain) and in normal cells from the lung, breast, orCancer Cell 12, 52–65, July 2007 ª2007 Elsevier Inc. 55
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protected during systemic delivery of suicide or proapop-
totic genes. Thus, the engineered promoter composite
C-VISA produced expression activity that was 3- to 4-
fold higher than that of the CMV promoter (as measured
by the TEI) in the pancreatic cancer cells tested; the com-
posite prolonged gene expression in vitro; and the gene
expression remained low in nonpancreatic cancer cells
and normal cells. This C-VISA vector should be ideal for
targeting a therapeutic gene to treat pancreatic cancer
in a gene therapy setting.
C-VISA Transcriptionally Targets Transgene
Expression in Pancreatic Cancer in Mouse Models
To determine whether the activity and specificity of C-
VISA can also be maintained in vivo, we next evaluated
the activity and expression of firefly luciferase driven by
C-VISA using the IVIS imaging system and immunohisto-
chemical analysis after intratumoral and intravenous sys-
temic delivery of the plasmid DNA:liposome complexes
in mice (Chen et al., 2004; Day et al., 2006; Li et al., 2003;
Templeton et al., 1997). First, to test the level and duration
of gene expression driven by C-VISA, CMV-Luc:liposome
or C-VISA-Luc:liposome complexes were injected into the
AsPC-1 tumors on the right and left flanks of nude mice.
The CMV (the plasmid containing the CMV enhancer/pro-
moter without Luc) and C-VISA (plasmid containing the
C-VISA promoter without Luc):liposome complexes were
used as negative controls. Bioluminescent imaging
showed that expression of the transgene firefly luciferase
was induced rapidly after injection of the CMV-
Luc:liposome complex, reached a peak on day 2, and
then decreased sharply thereafter (Figure 2A). However,
the expression of firefly luciferase induced by C-VISA-
Luc was significantly stronger and lasted longer than
that induced by CMV-Luc, reaching its peak on day 4
and lasting as long as 14 days (Figure 2A and data not
shown). Consistent with the in vitro data (Figure 1C), the
TEI of C-VISA in vivo was substantially higher than that
of CMV (3.2 versus 1). Second, to investigate the specific-
ity of gene expression driven by C-VISA, C-VISA-Luc:lipo-
some and CMV-Luc:liposome complexes were injected
into Hep3B (liver) tumor implants on the right and left
flanks of nude mice. Imaging showed that signal was
undetectable in the tumors treated with C-VISA-Luc com-
plexes, whereas it was strong in the tumors treated with
CMV-Luc (Figure 2B). Immunohistochemical analysis
confirmed that C-VISA induced stronger expression of
firefly luciferase in AsPC-1 tumors than did CMV-Luc
(Figure S2A) and undetectable expression of luciferase
in Hep3B tumors (Figure S2B).
Because our ultimate goal is to develop systemic gene
therapy for pancreatic cancer, we also evaluated the ex-
pression pattern of transgene driven by C-VISA in several
normal tissues after systemic delivery of plasmid DNA:
liposome complexes. To this end, C-VISA-Luc:liposome
and CMV-Luc:liposome complexes were intravenously
injected into mice bearing AsPC-1 pancreatic tumors. Bio-
luminescent imaging revealed a strong signal in the tho-56 Cancer Cell 12, 52–65, July 2007 ª2007 Elsevier Inc.racic area (lungs and heart) of mice treated with CMV-
Luc (Figure 2C). This finding indicated that after systemic
delivery, the complexes flowed through the circulatory
system, remaining mostly in the lungs and heart, and lucif-
erase was expressed because of the nonspecificity of the
CMV promoter. In contrast, a signal was almost undetect-
able in the thoracic area but was detected in the abdomen
of mice treated with C-VISA-Luc, indicating that C-VISA
targeted luciferase expression to the AsPC-1 tumors
after systemic delivery of the plasmid C-VISA-Luc
DNA:liposome complexes.
To more unambiguously determine the source of the
signal, the animals were humanely killed immediately after
in vivo imaging as described above and their organs were
dissected for ex vivo imaging. As shown in Figure 2D, the
lungs and hearts of mice treated with CMV-Luc produced
strong photon signals, causing the spots on the thoracic
area. The spots in the abdominal area were shown to be
from the pancreatic tumors of mice treated with C-VISA-
Luc. To further determine the tissue distribution of trans-
gene expression, tissue specimens from the tumors and
major organs of the treated mice were harvested and
tested for luciferase activity with a luminometer. Consis-
tent with the in vivo and ex vivo imaging results, luciferase
activity in the tumors of mice treated with C-VISA-Luc was
7.2-fold greater than that in the tumors of mice treated
with CMV-Luc (p < 0.01) (Figure 2E). In contrast, the lucif-
erase activity in the lungs and hearts of mice treated with
CMV-Luc was 1299- and 2314-fold, respectively, greater
than that in mice treated with C-VISA-Luc (p < 0.0001).
The cancer-specific index (i.e., luciferase activity in the tu-
mor compared with luciferase activity in the lungs) (Chen
et al., 2004) was 47.7 for C-VISA-Luc and 0.005 for
CMV-Luc. These findings indicate that C-VISA resulted
in a 9500-fold improvement in the selectivity of transgene
expression for tumor versus the usual site of vector se-
questration, the lung, after systemic administration com-
pared with the CMV promoter.
As mentioned earlier, a major determinant of the suc-
cess of cancer gene therapy is the ability to obtain suffi-
cient efficiency and specificity of transfection (Conwell
and Huang, 2005; Lo et al., 2005; Qiao et al., 2002), partic-
ularly for systemic nonviral delivery (Glover et al., 2005). To
determine the in vivo efficiency of systemic administration,
tissue specimens from the tumors and major organs of
mice were fixed, sectioned, and stained for luciferase ex-
pression using an anti-Luc antibody. Firefly luciferase pro-
tein staining demonstrated 22% ± 3% of tumor cells for in
vivo luciferase expression in orthotopic AsPC-1 tumors of
mice treated with C-VISA-Luc by intravenous injection, a
slightly higher percentage than CMV-Luc (18% ± 2.6%)
(Figure 2F). The staining signals of C-VISA-Luc, however,
were much stronger than those of CMV-Luc. The evi-
dence of in vivo luciferase expression analyzed by immu-
nohistochemistry was consistent with the findings from
the bioluminescent imaging and the luciferase activity
assay (Figures 2C, 2D, and 2E), showing that intravenous
treatment with CMV-Luc led to luciferase expression
in the lung (luciferase positive cells 18% ± 3%), liver
Cancer Cell
Targeting Eradication of Pancreatic CancerFigure 3. Expression of BikDD Driven by C-VISA Kills Pancreatic Cancer Cells Effectively and Specifically In Vitro
(A) Schematic diagram of expression constructs in the pUK21 backbone.
(B) BikDD expression driven by C-VISA kills PDAC cells effectively. The percentage of the signals as compared with the negative control (setting at
100%) was presented. The data represent the mean of three independent experiments. Error bars indicate SD.
(C) BikDD expression driven by C-VISA does not kill nonpancreatic cancer cells and normal cells. Error bars indicate SD.(10% ± 2%), and pancreas (1% ± 0.5%), whereas treat-
ment with C-VISA-Luc led to almost undetectable expres-
sion in these normal organs (Figure 2F). The results show
that the molecularly engineered CCKAR promoter com-
posite C-VISA transcriptionally targets transgene expres-
sion to pancreatic cancer in animal models. Thus, the
C-VISA vector could be an excellent candidate for the de-
velopment of a targeted, safe, and effective systemic
gene therapy system for patients with pancreatic cancer.
Expression of BikDD Driven by the C-VISA Promoter
Induces Death of Pancreatic Cancer Cells Effectively
and Specifically In Vitro
To examine whether the C-VISA vector can deliver a ther-
apeutic gene to selectively kill pancreatic cancer cells, we
generated a therapeutic plasmid in the pUK21 backbone,
pUK21-C-VISA-BikDD, in which the C-VISA vector drives
BikDD expression (Figure 3A). pUK21-CMV-BikDD was
used as a positive control (Figure 3A). To address the gen-
erality of C-VISA-BikDD for killing human PDAC, we tested
the killing effects of C-VISA-BikDD on 13 human PDAC
cell lines, one mouse PDAC cell line (Panc02), and one
sample of primary cultured human PDAC cells (PL5)
from a patient. Cells were transiently cotransfected with
pUK21-CMV-BikDD, pUK21-C-VISA-BikDD, or pUK21-
C-VISA (negative control) plus pGL3-CMV-Luc (the indi-
cator control). Cell killing effects were monitored with the
IVIS imaging system. C-VISA-BikDD effectively killed all
13 human PDAC cell lines, the mouse PDAC cell line, and
the primary cultured human PDAC cells, as comparable
with the CMV-BikDD (Figure 3B). However, C-VISA-BikDD
did not kill nonpancreatic cancer cells Hep3B (liver), U87
(brain), and normal lung fibroblasts WI-38, normal HPDE
cells E6E7, and rat pancreatic acinar cells AR42J (Fig-
ure 3C). In contrast, CMV-BikDD induced death of not only
pancreatic cancer cells (Figure 3B) but also all nonpancre-
atic cancer cells and normal cells tested (Figure 3C). Thus,
C-VISA-driven BikDD selectively kills pancreatic cancer
cells in vitro.C-VISA-BikDD Represses Tumor Growth More
Effectively Than CMV-BikDD in Orthotopic Models
of AsPC-1-Luc and Colo357FG Xenografts
To evaluate the antitumor effects of C-VISA-BikDD on
human pancreatic cancer in vivo, we first treated immuno-
deficient mice bearing orthotopic xenografts of human
pancreatic cancer cells (tumors were 100–150 mm3 [as
measured postmortem with calipers], corresponding to
1.4 3 107 photons/tumor/second [as measured with the
IVIS imaging system] with systemic delivery of liposomal
C-VISA-BikDD complexes). Nude mice bearing the ortho-
topic AsPC-1-Luc pancreatic tumors were treated with
doses of 5 mg, 15 mg, or 45 mg of C-VISA-BikDD or 45 mg
of C-VISA (Ctrl) in a liposomal complex via tail-vein injec-
tion, twice per week for 3 weeks (six applications total)
based on the expression pattern and transfection effi-
ciency of luciferase reporter gene in vivo described above.
Tumors were noninvasively monitored in vivo with the IVIS
imaging system. Compared with the control, treatment
with C-VISA-BikDD significantly reduced signal from the
tumors in a dose-dependent manner (Figure 4A).
To compare the antitumor effects of C-VISA-BikDD with
those of CMV-BikDD, nude mice bearing AsPC-1-Luc tu-
mors were given 15 mg of CMV-BikDD, C-VISA-BikDD, or
C-VISA (Ctrl) in a liposomal complex via tail vein injection,
twice per week for 3 weeks. Imaging revealed that treat-
ment with either CMV-BikDD or C-VISA-BikDD led to sig-
nificantly decreased signal from the tumors 1 week after
starting treatment (both p < 0.0001 versus control) (Fig-
ure 4B). Furthermore, C-VISA-BikDD decreased the signal
to a greater extent than did CMV-BikDD (p < 0.05 on day
21 and p < 0.01 on day 28), indicating that C-VISA-BikDD
inhibited growth of human-derived pancreatic cancer
more effectively than did CMV-BikDD (Figure 4B). CMV-
BikDD also prolonged the median survival time of mice
compared with the control (52 ± 8 days versus 31 ± 4
days, p < 0.004). Moreover, C-VISA-BikDD prolonged sur-
vival more effectively than did CMV-BikDD (p < 0.01)
(Figure 4C). Signal was undetectable in five of eight miceCancer Cell 12, 52–65, July 2007 ª2007 Elsevier Inc. 57
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Targeting Eradication of Pancreatic CancerFigure 4. Expression of BikDD Driven by C-VISA Promoter Inhibits Tumor Growth and Prolongs Mouse Survival More Effectively
Than That Driven by CMV Promoter in Orthotopic Xenograft Models
(A) Expression of BikDD driven by C-VISA promoter inhibited tumor growth in a dose-dependent manner. Nude mice bearing AsPC-1-Luc tumors
were systemically given liposomal plasmid DNA at indicated doses (n = 8 mice/group). The photon signals were quantified with Xenogen’s living
imaging software. Error bars indicate SEM.
(B–D) Expression of BikDD driven by C-VISA promoter inhibited human pancreatic tumor growth of AsPC-1 and prolonged mouse survival more
effectively than BikDD driven by CMV promoter. Nude mice bearing AsPC-1-Luc tumors were intravenously injected with 15 mg of liposomal plasmid
DNA as above (n = 8 mice/group). (B) The photon signals (left panel) were quantified with Xenogen’s living imaging software and representative images
are shown (right panel). Error bars indiacte SEM (C) Kaplan-Meier survival analysis was performed. Data shown are representative of two separate
experiments. (D) In vivo apoptosis of tissue specimens was analyzed. The percentages of apoptotic cells from five fields of the indicated tissues are
shown (lower panel). (E) Expression of BikDD driven by C-VISA promoter inhibited human pancreatic tumor growth of Colo357FG. Two weeks after
the last treatment, mice were killed, and the tumors were dissected and weighed. Error bars indicate SD.(62.5%) at 60 days after treatment in the C-VISA-BikDD
group. After 14 months, four of those five mice treated
with C-VISA-BikDD still showed no detectable signal, sug-
gesting that tumors did not recur. To assess apoptosis
in vivo after treatment, 2 days after the second administra-
tion of the BikDD complexes three mice per group were
killed and their tumors sectioned for apoptosis detection
by terminal deoxynucleotidyl transferase [TdT]-mediated
dUTP nick end labeling (TUNEL) assay. Both C-VISA-
BikDD and CMV-BikDD induced substantial tumor cell
apoptosis. However, CMV-BikDD also led to remarkable
apoptosis in the lung tissue, but C-VISA-BikDD did not
(Figure 4D), indicating that C-VISA induced BikDD expres-
sion in the targeted pancreatic tumor cells but not in the
normal tissues such as lungs. Consistent with the tumor
growth and mouse survival results, C-VISA-BikDD58 Cancer Cell 12, 52–65, July 2007 ª2007 Elsevier Inc.showed more potent apoptosis than did CMV-BikDD (p <
0.007) (Figure 4D). To examine the antitumor effects of
C-VISA-BikDD in multiple models, we further investigated
the in vivo repression of Colo357FG and Colo357L3.6pl
tumor growth by systemic administration of C-VISA-
BikDD in orthotopic nude mouse models. BALB/c nu/nu
nude mice bearing Colo357FG or Colo357L3.6pl tumors
were treated as described above. The mice were killed
and the tumors were dissected and weighed 2 weeks
following the last treatment. We found that systemic ad-
ministration of liposomal C-VISA-BikDD vector inhibited
human pancreatic tumor growth of Colo357FG (p < 0.001,
versus Ctrl) (Figure 4E) and of Colo357L3.6pl (p < 0.01,
versus Ctrl) (Figure S3). It is worthwhile to mention that
even the expression level of luciferase driven by C-VISA
is slightly lower than that by the CMV promoter in
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Targeting Eradication of Pancreatic CancerFigure 5. Expression of BikDD Driven by C-VISA Promoter Inhibits Tumor Growth and Invasion/Metastasis and Prolongs Mouse
Survival More Effectively Than That Driven by CMV Promoter in an Orthotopic Syngeneic Model
(A–C) Expression of BikDD driven by C-VISA promoter inhibited tumor growth and prolonged mouse survival more effectively than BikDD driven by
CMV promoter. C57BL/6 mice bearing Panc02-Luc tumors were treated as described above and were subjected to in vivo imaging. (A) The photon
signals were quantified with Xenogen’s software (n = 8 mice/group) and representative images are shown (right panel). Error bars indicate SEM. (B)
Kaplan-Meier survival analysis from (A). (C) In vivo apoptosis of tissue specimens was analyzed. The percentages of apoptotic cells from five fields of
the indicated tissues are shown (lower panel). Error bars indicate SD.
(D) C-VISA-BikDD inhibits invasion/metastasis of Panc02 tumors in an orthotopic syngeneic model. The mice with Panc02 tumors were treated as
described in Figure 6A and subjected to in vivo imaging on day 28 after the first treatment. The mice were then killed, the dissected tumors and organs
were imaged ex vivo (left panels), and the signals were quantified (right panels). Error bars indicate SEM; Tu, tumor; Pan, pancreas; Tu/Pan, tumor
and/or pancreas.Colo357L3.6pl pancreatic cancer cell line based on the
luciferase activity 2 days after transfection (Figure S1B),
the therapeutic efficacy of C-VISA-BikDD tested in the xe-
nograft model is slightly better than or at least comparable
to that of CMV-BikDD. This may be due to the fact that
the C-VISA vector prolongs expression of the transgene
resulting in increased TEI (Figure 1C) and therapeutic effi-
cacy should be more related to the TEI than to the expres-
sion level on a particular day (Figure 1B and Figure S1B).
Thus, C-VISA-BikDD induced targeted apoptosis, re-
pressed tumor growth in a dose-dependent manner, and
suppressed tumor growth more effectively than did CMV-
BikDD in multiple orthotopic models of human pancreatic
cancer.
C-VISA-BikDD Inhibits Tumor Growth
and Metastasis and Prolongs Mouse Survival More
Effectively Than CMV-BikDD in an Orthotopic
Syngeneic Model of Panc02-Luc Tumor
Because nude mice are immunodeficient, the nude mouse
xenograft model cannot be used to address the role of the
immune system in affecting tumor growth and repeatedplasmid administration. These issues will be important
clinically if the therapeutic efficacy of C-VISA-BikDD can
be examined in an intact immunocompetent mouse
model. To this end, we explored use of a syngeneic mouse
pancreatic tumor model (Yan et al., 2006). Female C57BL/
6 mice bearing established orthotopic Panc02-Luc tumors
(100–150 mm3 [as measured postmortem with calipers],
corresponding to 53 106 photons/tumor/second [as mea-
sured with the IVIS imaging system]) were treated as de-
scribed above. In contrast to the control mice, in which
the strength of signals increased over time, the signals
from mice treated with CMV-BikDD or C-VISA-BikDD were
much weaker just 14 days after the first treatment (p < 0.01
and p < 0.009, respectively, versus Ctrl) (Figure 5A). As in
the xenograft model, C-VISA-BikDD decreased the sig-
nals to a greater extent than did CMV-BikDD (p < 0.05
on day 21 and p < 0.02 on day 28), indicating that C-
VISA-BikDD inhibited tumor growth more effectively than
CMV-BikDD. Although CMV-BikDD consistently and sig-
nificantly prolonged the median survival time of mice com-
pared with the control (40 ± 3 days versus 30 ± 2 days, p <
0.0003), C-VISA-BikDD prolonged mouse survival evenCancer Cell 12, 52–65, July 2007 ª2007 Elsevier Inc. 59
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the C-VISA-BikDD treatment group, signal was undetect-
able in five of eight mice at 60 days after treatment; at 14
months, those five mice still showed no detectable signal,
suggesting that their tumors had been eradicated. Apo-
ptosis induction by C-VISA-BikDD was more potent than
that by CMV-BikDD (p < 0.002) (Figure 5C). Therefore,
the therapeutic efficacy of C-VISA-BikDD can be demon-
strated both in an immunodeficient mouse model with
human pancreatic tumor cells and in an intact immuno-
competent mouse model with murine pancreatic tumors.
Owing to the highly aggressive nature of Panc02 cells,
orthotopic Panc02 tumors easily invade and metastasize
to local and distant sites (Yan et al., 2006). To investigate
whether C-VISA-BikDD could inhibit invasion or metasta-
sis of Panc02 tumors, mice treated as described in the
previous section were subjected to imaging in vivo and
ex vivo at 28 days after the first treatment. Ex vivo imaging
showed that Panc02 tumors in the pancreas of control
mice were the largest (2.5 ± 0.5 g) and also invaded or
metastasized to the peritoneal omentum, intestinal mes-
entery, liver, spleen, kidneys, bladder, lungs, and bone
(metastatic tumors ranged from 50 mg to 1.5 g) (Figure 5D).
Tumors in the pancreas of CMV-BikDD-treated mice were
much smaller (50 ± 12 mg), and only a few very small
tumors were found in the surrounding organs. Almost no
signal was detected in the abdominal cavity of C-VISA-
BikDD-treated mice, indicating that the treatment pre-
vented metastases from developing (Figure 5D).
C-VISA-BikDD Produces Virtually No Acute Toxicity
Compared With CMV-BikDD
To characterize whether treatment with C-VISA-BikDD is
safer than CMV-BikDD in preclinical experiments, we
evaluated systemic toxic effects in the female C57BL/6
mice that had been used for the syngeneic pancreatic
tumor experiments (Figure 6). Single doses of 2.5 or 5 mg
plasmid DNA/kg mouse weight were given by tail-vein in-
jection in a volume of 100 ml of DNA:liposome complexes.
Ten of ten (100%) mice treated with a single 5 mg/kg
(100 mg per mouse) dose of CMV-BikDD died the next
day. However, only two of ten mice treated with a single
5 mg/kg dose of C-VISA-BikDD died during the first 2
days and the surviving mice remained alive for more than
3 months without any obvious symptoms when the exper-
iment was terminated (Figure 6A, left panel and data not
shown) (p < 0.004 versus CMV-BikDD). All of the animals
were alive with no evidence of toxic effects after treatment
with a single 2.5 mg/kg (50 mg per mouse) dose of C-VISA-
BikDD (Figure 6A, right panel). Blood samples were col-
lected from all living mice after treatment with a single
50-mg dose of C-VISA-BikDD or CMV-BikDD, and serum
levels of liver aspartate aminotransferase (AST), alanine
aminotransferase (ALT), and blood urea nitrogen (BUN)
were measured. Treatment with CMV-BikDD generated
6.5- and 11.7-fold increases in AST levels, and 25- and
24-fold increases in ALT levels on day 1 and day 2, respec-
tively, indicating that CMV-BikDD caused severe acute
liver toxicity. However, treatment with C-VISA-BikDD did60 Cancer Cell 12, 52–65, July 2007 ª2007 Elsevier Inc.not increase the levels of AST or ALT, indicating minimal
(if any) liver toxicity in the surviving mice (Figure 6B).
BUN levels were not elevated at any measurement time
(data not shown), indicating a lack of nephrotoxicity of both
CMV-BikDD and C-VISA-BikDD. Hematoxylin and eosin
staining (H&E) showed that mice treated with C-VISA-
BikDD had no pathological changes in major organs rela-
tive to the control mice. Notably, systemic administration
of C-VISA-BikDD plasmid in a liposomal complex at a ther-
apeutic dose of 0.75 mg/kg (15 mg/mouse) resulted in no
obvious toxic effects in C57BL/6 or BALB/c nu/nu mice,
i.e., no elevated liver enzymes, moribund behavior, or
death, and the mice looked healthy during the course of
the experiments (data not shown).
To further investigate whether there is any evidence of
underlying acute pancreatitis in C-VISA-treated mice, we
performed the toxicity experiment in C57BL/6 mice by
measuring pancreatic exocrine enzyme levels, H&E and
TUNEL analysis. Cerulein-induced acute pancreatitis
was used as positive control. As illustrated in Figure 6C,
no differences were observed at the levels of serum amy-
lase (p = 0.6) and pancreatic active trypsin activity (p = 0.1)
between the C-VISA-BikDD-treated mice and the C-VISA
control mice (Ctrl). However, treatment with CMV-BikDD
induced a significant increase in the levels of serum amy-
lase (p < 0.001 versus Ctrl) and pancreatic active trypsin
activity (p < 0.002 versus Ctrl). As expected in the positive
control group, treatment with supraphysiologic amount of
cerulein induced both elevated levels of serum amylase
and pancreatic active trypsin activity (Figure 6C). In addi-
tion, histological examination of the pancreas from mice
treated with C-VISA-BikDD, CMV-BikDD and C-VISA con-
trol vector, showed no evidence of parenchymal edema,
pancreatic epithelial vacuolization and necrosis/apopto-
sis, and inflammatory cell infiltration; however, there was
an overt onset of acute pancreatitis induced by cerulein.
Furthermore, no TUNEL-positive cells appeared in the
acinar and ductal cells of the pancreata of mice treated
with C-VISA-BikDD as compared with the control mice
treated with C-VISA, in contrast to apoptotic positive cells
of the pancreata of mice treated with CMV-BikDD (1.5%
TUNEL-positive cells) and with cerulein (4.5% TUNEL-
positive cells) (Figure 6D). Taken together, treatment with
C-VISA-BikDD produces virtually no systemically acute
toxicity (Figures 6A and 6B) or acute pancreatitis (Figures
6C and 6D).
DISCUSSION
A key determinant of safe and effective treatment for can-
cer is the ability to target cancer cells both at the site of the
primary tumor and at distant metastatic sites (Zhou and
Bartek, 2004). Transductional targeting and transcrip-
tional targeting are two primary approaches that are used.
Transcriptional targeting is of particular importance in
liposome-based systemic gene delivery (Qiao et al.,
2002; Reynolds et al., 2001). With the goal of developing
a robust and pancreatic-cancer-specific vector, we
previously identified the CCKAR promoter as a
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Targeting Eradication of Pancreatic CancerFigure 6. C-VISA-BikDD Has No Systemically Acute Toxicity Compared With CMV-BikDD in Mice
(A and B) C-VISA-BikDD has no systemically acute toxicity compared with CMV-BikDD. (A) Kaplan-Meier survival analysis. Female C57BL/6 mice
were given single doses of 100 mg (left panel) or 50 mg (right panel) plasmid DNA in a liposomal complex via the tail vein. (B) Kinetics of serum levels
of AST and ALT after a single intravenously injection of 50 mg liposomal plasmid DNA. Error bars indicate SD; AST, aspartate aminotransferase; ALT,
alanine aminotransferase.
(C and D) C-VISA-BikDD has no acute pancreatic toxicity compared with CMV-BikDD and cerulein treatment in mice. (C) Serum amylase (left) and
pancreatic trypsin (right) activity were shown. Data are means minus the basal level of mice treated with normal saline (NS). Error bars indicate stan-
dard deviation. (D) Morphologic (H&E) and apoptosis (TUNEL) analysis of pancreas from mice treated with cerulein. Arrows indicate examples of
necrotic cells in cerulein group (H&E) or apoptotic cells in cerulein and CMV-BikDD groups; arrow head indicates an example of inflammatory cell
infiltration in cerulein group (H&E). The percentage of apoptotic cells were measured by positive TUNEL staining from 10 fields.pancreatic-cancer-specific promoter (Li et al., 2006).
CCKAR expression is known to be upregulated in the duc-
tal cells of the human PDAC as compared to the normal
pancreatic cells by multiple independent groups (Goetze
et al., 2000; Jang et al., 2005; Moonka et al., 1999; Wein-
berg et al., 1997), except for one (Reubi et al., 2003). To
clarify this issue, we also performed the experiments.
The results supported the former (Figure S1A). The trun-
cated CCKAR promoter, ranging from 726 to +1, and
our engineered C-VISA showed undetectable activity or
significantly lower activity than the CMV promoter, in can-
cer cells of nonpancreatic origin in vitro (Figure 1D) and in
normal mouse tissues in vivo (Figure 2). C-VISA is a com-posite that contains three basic elements: the CCKAR
promoter, the TSTA system, and the WPRE sequence.
C-VISA-BikDD selectively controls expression of BikDD
in PDAC, involving four steps as illustrated in Figure 7:
(1) CCKAR drives the expression of the GAL4-VP2 (two
copies of VP16) fusion protein selectively in PDAC but
not in normal cells; (2) GAL4-VP2, which contains a yeast
GAL4 DNA-binding domain and a strong transactivation
domain derived from HSV-1 VP16, then turns on target
gene BikDD mRNA transcripts under the control of GAL4
response elements in a minimal promoter G5E4T recog-
nized by the GAL4 DNA-binding domain within the same
plasmid; (3) the BikDD mRNA transcripts contains theCancer Cell 12, 52–65, July 2007 ª2007 Elsevier Inc. 61
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Targeting Eradication of Pancreatic CancerFigure 7. Schematic Diagram of the C-VISA-BikDD System
The C-VISA-BikDD system involves four steps in human PDAC. (1) CCKAR drives the expression of the GAL4-VP2 fusion protein selectively in PDAC
but not in normal cells; (2) GAL4-VP2 then turns on target gene BikDD mRNA transcripts; (3) the BikDD mRNA transcripts contains the WPRE element,
which stabilizes RNA transcripts; and (4) the stabilized BikDD mRNA transcripts enhance and prolong duration of BikDD protein expression, leading
to apoptosis of PDAC cells. For normal cells or normal pancreas, the CCKAR promoter is much less active, resulting in very limited target gene
expression and, therefore, cell survival.WPRE element, which stabilizes RNA transcripts; and (4)
the stabilized BikDD mRNA transcripts enhance and pro-
long duration of BikDD protein expression, leading to apo-
ptosis of PDAC cells. Whereas for normal cells or normal
pancreas, the CCKAR promoter is much less active, result-
ing in very limited target gene expression and therefore cell
survival. Thus, C-VISA is much better than C-TSTA or CMV
in activity and TEI (Figures 1 and 2). The pancreatic-cancer-
specific index of C-VISA was significantly higher than that
of the CMV promoter (47.7 versus 0.005), representing
a 9500-fold improvement. The VISA system is also a versa-
tile tool to boost other tissue- or cancer-specific promoters
for developing promising therapeutics for other diseases.
One of the major technical challenges of nonviral gene
delivery approaches is the inefficiency of systemic delivery
and transgene expression (Conwell and Huang, 2005;
Glover et al., 2005; Lo et al., 2005; Qiao et al., 2002). Ex-
truded DOTAP:cholesterol liposomes can complex with
plasmid DNA to form turbid colloidal particles with a
mean size of 405 nm in diameter and a half-life of at least
5 hr in circulation, leading to enhanced expression of trans-
gene in most tissues (Templeton et al., 1997). Here, we
complexed extruded DOTAP:cholesterol liposomes with
reporter plasmid DNA in which the luciferase gene is under
the control of the robust C-VISA vector. After systemic de-
livery of C-VISA-Luc:liposome complexes in vivo in multi-
ple orthotopic models, monitoring with the IVIS imaging
system and traditional methods showed that transgene
expression was effectively targeted to the pancreatic tu-
mors. The high level of in vivo target luciferase expression
(about 22%) (Figure 2F) was obtained in the orthotopic62 Cancer Cell 12, 52–65, July 2007 ª2007 Elsevier Inc.AsPC-1 tumors of mice after a single injection of a liposo-
mal C-VISA-Luc complex.
The highly efficient transgene targeting using C-VISA in
DNA:liposome complexes makes it feasible to develop
a safe and effective nonviral-mediated gene therapy strat-
egy. Here we rigorously tested the antitumor effects of
BikDD driven by C-VISA in plasmid DNA:liposome com-
plexes injected via the tail vein in xenograft and syngeneic
orthotopic mouse models by using imaging of live animals
and traditional methods. Our findings demonstrated that
C-VISA-BikDD induced apoptosis of targeted pancreatic
tumor cells, repressed tumor growth, and prolonged
mouse life span more effectively than CMV-BikDD in both
models. Also worthwhile to mention is that the tumor sup-
pressor gene p53 is known to be inactivated by mutations
in 40%–75% of pancreatic adenocarcinomas (Bardeesy
and DePinho, 2002; Hingorani et al., 2005; Li et al., 2004).
The lack of functional p53 has been reported to be a com-
ponent of resistance to DNA-damaging agents, resulting
in the inhibition of apoptosis (Zhou and Bartek, 2004); in-
deed, p53-negative AsPC-1 cells are resistant to p53-
mediated apoptosis (Rodicker and Putzer, 2003). Our
findings showed that treatment with C-VISA-BikDD effec-
tively led to apoptotic death of AsPC-1 cells in vitro and
in vivo. More importantly, BikDD expression driven by
the C-VISA promoter induced pancreatic-cancer-specific
apoptosis in vitro and in vivo in agreement with the selec-
tivity of the C-VISA vector. This specificity was further
reflected in the systemic acute toxicity profile. Systemic
administration of C-VISA-BikDD was much less toxic
than CMV-BikDD in C57BL/6 mice.
Cancer Cell
Targeting Eradication of Pancreatic CancerOur established orthotopic mouse models and our live
animal imaging capability have made it possible for nonin-
vasive, spatiotemporal monitoring of the growth and
metastasis of pancreatic tumors. In traditional models of
orthotopic pancreatic cancer, monitoring tumor growth,
especially the identification of metastases, is difficult even
at necropsy. For these studies, we generated two ortho-
topic pancreatic cancer models, syngeneic Panc02-Luc
and xenograft AsPC-1-Luc, in which primary and meta-
static tumors glow from the expression of firefly luciferase
after injection of D-Luciferin. Our real-time monitoring
models not only facilitated the localization of tumors and
metastases but also reduced the number of animals re-
quired for the studies.
In summary, we have engineered C-VISA, a stringently
pancreatic-cancer-specific expression vector that in-
duces longer and stronger transgene expression than
the CMV promoter-driven expression vector in vitro and
in vivo. C-VISA targets transgene expression to pancre-
atic cancer in vivo in animal models. Expression of a potent
proapoptotic Bik mutant gene (BikDD) driven by C-VISA
after systemic liposome-mediated delivery exhibits signif-
icant antitumor effects on pancreatic cancer and prolongs
survival in multiple orthotopic xenograft and syngeneic
mouse models of pancreatic tumors with minimal or no
toxic effects. Overall, this study demonstrates the feasibil-
ity of C-VISA-BikDD:liposome complexes as a safe and
highly effective gene therapy strategy for pancreatic can-
cer and is worthy of further development into clinical trials.
The versatile VISA system can also be applied to other
tissue- or cancer-specific promoters for the development
of promising therapeutics for other diseases.
EXPERIMENTAL PROCEDURES
Cell Culture
For sources of cell lines and culture media, see the Supplemental Data.
All patients provided informed consent with institutional review board
approval of all protocols.
Constructs
The constructs including pGL3-CCKAR-Luc-(C-Luc), pGL3-CCKAR-
Luc-WPRE (C-P-Luc), pGL3-CCKAR-TSTA-Luc (C-T-Luc), pGL3-
CCKAR-TSTA-Luc-WPRE (C-VISA-Luc), pGL3-CMV-Luc (CMV-Luc),
pUK21-CMV-BikDD (CMV-BikDD), and pUK21-C-VISA-BikDD (C-
VISA-BikDD) were generated according to the standard molecular
cloning protocol.
Animal Models of Pancreatic Cancer, Delivery of Plasmid DNA
and Imaging Analysis
Mice were maintained in a specific pathogen-free environment in com-
pliance with institutional policy and all animal procedures were previ-
ously approved by the appropriate institutional review boards. The
subcutaneous and orthotopic models were established as described
previously (Wen et al., 2001; Xie et al., 2001). The growth and metas-
tasis of tumors were monitored in real time with the IVIS imaging sys-
tem, equipped with Living Imaging software (Xenogen, Alameda, CA).
For details on the treatments and analysis, see the Supplemental Data.
Imaging and Quantification of Bioluminescence Data
Mice were anesthetized with a mixture of oxygen and isoflurane (Inha-
lation Anesthesia System; Matrix Medical, Orchard Park, NY) and in-
traperitoneally injected with 100 ml of D-luciferin (Xenogen; 30 mg/mlin phosphate-buffered saline [PBS]). Ten minutes after injection, mice
underwent imaging with the IVIS Imaging System (Xie et al., 2004).
Imaging parameters were maintained for comparative analyses. The
imaging results were analyzed with the manufacturer’s software (Living
Imaging, version 2.5; Xenogen). A region of interest (ROI) was manually
selected over relevant regions of signal intensity. The ROI was kept
constant, and the intensity was recorded as the maximum number of
photon counts within an ROI (Iyer et al., 2001; Xie et al., 2004).
In vivo cell imaging was performed 5 min after the addition of D-luciferin
at a final concentration of 5 ng/ml. Bars indicate standard error (SEM).
Analysis of Acute Toxic Effects Induced by Systemic
Administration in Mice
C57BL/6 mice were studied for evidence of acute toxic effects induced
by systemic administration of DNA:liposomal complexes. Levels of se-
rum AST, ALT, and BUN were measured at the biochemistry laboratory
in the Department of Veterinary Medicine and Surgery. Serum amylase
activity was determined using the Phadebas Amylase Test Kit (Magle
Life Sciences, Lund, Sweden). The pancreatic tissue was homoge-
nized and assayed for active trypsin (Lugea et al., 2006). Trypsin activ-
ity was calculated according to a standard curve from purified trypsin
(Sigma). Shown in Figure 6C are the means subtracted from the basal
levels of serum amylase and trypsin activity, respectively, of the NS
controls.
Statistical Analyses
Analysis of variance was used to compare the differences among the
treatment groups. Survival rates were analyzed by log-rank test (Man-
tel-Cox test) using SSPS 12.1 software. The significance level was set
at p < 0.05.
Additional Experimental Procedures
Detailed descriptions are provided in the Supplemental Data.
Supplemental Data
The Supplemental Data include Supplemental Experimental Proce-
dures and three supplemental figures and can be found with this article
online at http://www.cancercell.org/cgi/content/full/12/1/52/DC1/.
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